This repressive monomania stabs even deeper into our freedom of expression by concocting a "right" of right-wing vigilantes to enforce the ordinances. Yes, self-appointed bands of bounty hunters would be authorized to roam the countryside suing local libraries (and individual librarians) for having "banned" books on the shelves. To spur this political malice, Mitchell's scheme provides a $10,000 reward for every violation a vigilante finds (or fabricates).

Well, you say, thank God I don't live in Texas! But — Hello! — repression doesn't recognize state borders, so the pernicious idea of paid library marauders is spreading across the country. To help defend your freedom from them, go to the American Library Association: ala.org.

How Despicable Are Big Pharma's Price Gougers?

Profiteering is always bad, but there are degrees of profiteer. Level 1 includes your everyday price gougers, like banks and airlines. At Level 2, you'll find the more demonic outfits like loan sharks and for-profit college hucksters. Then, top of the heap at Level 3, you'll find Eli Lilly.

This $288 billion drug-making colossus is America's primary peddler of insulin, the diabetes drug that some seven million Americans must constantly take literally to stay alive. By having both monopoly power over the market and such a huge base of captive customers, Lilly has gleefully jacked up its prices again and again over three decades, with insulin now costing each sufferer as much as $1,000 a month! Finally, under intense political pressure to stop its extreme, life-threatening gouging, the giant recently announced it would soon cut its insulin price by a whopping 70 percent! In full-page ads, Lilly hailed its corporate generosity, magnanimously declaring that "everyone deserves affordable options."

But — Hello! — it has intentionally charged unaffordable rip-off prices for 30 years, wallowing in monopoly profits. And — Hello! again — if Lilly says it can keep profiting on its insulin product despite slashing the price by 70%, that means it has been overcharging patients by 70 percent all this time! Yet, its rich executives want us to thank them? No thank you.

Even with the price cut, they're still charging $66 for a single vial of insulin. Guess what? It costs Lilly less than $7 to produce that vial, and it could be sold profitably for under $9.

Meanwhile, note that the ballyhooed price cut is voluntary, meaning Lilly can raise the price again at any time. Indeed, David Ricks (who personally pockets $19 million a year from the profiteering) has refused to pledge that he'll keep the medicine affordable.

To find out more about Jim Hightower and read features by other Creators Syndicate writers and cartoonists, visit the Creators webpage at www.creators.com.